San Diego, CA, United States of America

Kalyanaraman Ramnarayan

USPTO Granted Patents = 3 

Average Co-Inventor Count = 8.2

ph-index = 3

Forward Citations = 81(Granted Patents)


Company Filing History:


Years Active: 1996-2003

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kalyanaraman Ramnarayan: Innovator in Endothelin Modulation

Introduction

Kalyanaraman Ramnarayan is a notable inventor based in San Diego, CA, with a focus on innovative solutions in the field of biochemistry. He holds three patents that contribute significantly to the understanding and treatment of endothelin-mediated disorders.

Latest Patents

His latest patents include the development of benzenesulfonamides that modulate the activity of endothelin. These patents detail methods for inhibiting the binding of endothelin peptides to their receptors, as well as increasing the activity of these peptides through the use of specific sulfonamides. Notably, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides have been highlighted for their potential as endothelin receptor B antagonists. Furthermore, his work includes methods for treating inflammatory diseases, such as asthma, by administering effective amounts of these sulfonamides or their prodrugs.

Career Highlights

Kalyanaraman has worked with several prominent companies, including Texas Biotechnology Corporation and Structural Bioinformatics Inc. His contributions in these roles have been instrumental in advancing research and development in his field.

Collaborations

He has collaborated with notable professionals such as Venkatachalapathi Yalamoori and Ming Fai Chan, enhancing the impact of his work through teamwork and shared expertise.

Conclusion

Kalyanaraman Ramnarayan's innovative contributions to the field of endothelin modulation demonstrate his commitment to advancing medical science and improving treatment options for various disorders. His patents and collaborations reflect a significant impact on biochemistry and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…